Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 4

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Nephrol. Jul 6, 2016; 5(4): 308-320
Published online Jul 6, 2016. doi: 10.5527/wjn.v5.i4.308

Table 3 Possible treatment of C3 glomerulopathies

Nonspecific treatment

Replace deficient gene products

Plasma infusion

Liver Transplantation

Eliminate autoantibodies and/or mutant proteins

Plasma exchange

Immunosuppression

Treatment of plasma cell dyscrasia

Inhibition of complement activation

Eculizumab (anti C5)

Inhibition of the C3 Convertase

Renal transplantation

New trials ongoing

Citation: Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol 2016; 5(4): 308-320
URL: https://www.wjgnet.com/2220-6124/full/v5/i4/308.htm
DOI: https://dx.doi.org/10.5527/wjn.v5.i4.308

Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol 2016; 5(4): 308-320 [PMID: 27458560 DOI: 10.5527/wjn.v5.i4.308]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.